Hepatitis B virus (HBV) infection is more aggressive in individuals coinfected with human immunodefi ciency virus (HIV): in the presence of HIV, HBV carrier rates and viremia levels are higher, episodes of activation are more frequent, cirrhosis progresses more quickly, and hepato cellular carcinoma occurs more often than with HBV infection alone. As in HBV monotherapy,
W
orldwide, 40 million people are infected with the human immunodefi ciency virus (HIV). As many as 4 million of them are coinfected with hepatitis B virus (HBV). 1 In North America and Europe, the highest prevalence of HBV/HIV coinfection is in men who have sex with men. Approximately half of HIV-positive men who have sex with men have evidence of prior or active HBV infection, and 5% to 10% have chronic HBV infection. Among those who acquire HIV through injected drug use or through heterosexual transmission, the coinfection rate is much lower. 2, 3 Coinfection with HBV and HIV follows a different course elsewhere in the world. For example, in Africa and Asia, HBV is usually acquired fi rst through neonatal or childhood infection, with either vertical or horizontal transmission after birth. 4, 5 In parts of Africa, ritual scarifi cation is likely a major player in the adolescent transmission of HBV. (Ritual scarifi cation is the practice of creating small incisions in the skin of adolescents and rubbing black ash in the wounds to form scars; the cutting instruments are not sterilized between rituals.)
NATURAL HISTORY
In general, HBV tends to be more aggressive in HIVpositive individuals than in monoinfected individuals, 2, 6 with higher HBV carrier rates, higher levels of HBV viremia, more frequent episodes of activation, and faster progression to cirrhosis.
Hepatocellular carcinoma occurs more often, its onset is earlier, and its course is more aggressive in coinfected individuals than in monoinfected individuals. 7, 8 Using data from a prospective cohort study, Thio et al 9 found that among men coinfected with HIV and HBV, liver-related mortality was almost 19 times greater compared with men infected with HBV only and more than seven times greater compared with those infected with HIV only.
In an observational longitudinal cohort study, 10 the risk of death from liver disease in HIV-positive persons was nearly three times greater among those also infected with HBV (P < .0001).
an undetectable level, which will result in normalization of alanine aminotransferase (ALT) level, improved liver histology, reduced risk of progression to cirrhosis and liver failure (although supportive evidence from controlled clinical trials is lacking), and likely reduced incidence of hepatocellular carcinoma.
For those who are hepatitis B e antigen (HBeAg) positive, seroconversion may be a convenient end point for treatment, although for many patients seroconversion is not associated with remission of disease activity or viral replication.
Treatment decisions depend on whether or not the patient requires highly active antiretroviral therapy (HAART) for HIV infection. If HAART is indicated, then HIV agents that have HBV activity are incorporated into the regimen. If the patient does not yet require HAART for HIV but requires treatment for hepatitis B, this is itself an indication for HAART, since monotherapy for HBV is associated with the development of HIV resistance.
Viral load and ALT
As with treatment of chronic HBV infection, the approach to the patient coinfected with HBV and HIV starts with an assessment of HBV DNA level ( Figure  1 ). 2 Those with HBV DNA levels less than 2,000 IU/ mL, indicating the absence of active replicating disease, do not require anti-HBV therapy as long as their viral load remains low. These patients should have their HBV DNA levels monitored regularly for a change in status. If the HBV DNA level is 2,000 IU/mL or higher, the treatment decision should be based on the ALT level. If the ALT is elevated, even intermittently, anti-HBV treatment should be instituted.
Liver biopsy
If the ALT is normal in the presence of a high HBV DNA level, a liver biopsy is recommended, partly because the ALT level is an inadequate indicator of the severity of liver disease. If signifi cant fi brosis is present, treatment is recommended. No treatment is required if fi brosis is mild, but liver biopsies should be repeated every 3 to 5 years in this group because a hallmark of HBV infection is its variability in time to progression. The extent of fi brosis may infl uence the choice of therapy.
Often in the coinfected patient, HBV-related liver injury must be distinguished from other forms of liver injury. For instance, some of the drugs used to treat HIV infection can induce non alcoholic fatty liver disease and lipodystrophy. Because the risk of advanced fi brosis is higher in the coinfected patient than in the patient infected only with HBV, the threshold for biopsy in the coinfected patient should be lower.
At present, noninvasive tools to assess the extent of liver injury have not been validated in chronic HBV infection, unlike in hepatitis C virus infection.
TREATMENT OPTIONS
The potential therapies for HBV in the coinfected patient are the same as those for the patient infected with HBV alone (see "Hepatitis B treatment: Current best practices, avoiding resistance," page S14), with the addition of tenofovir and emtricitabine in combination.
Interferon
Early studies of interferon for the treatment of chronic HBV infection included many patients who were also HIV positive. These early studies revealed a lower rate of HBeAg seroconversion in HIV-positive patients compared with HIV-negative patients. Di Martino et al 11 found that approximately half (26 of 50) of HIVnegative patients treated with interferon seroconverted at 6 years, compared with only 4 of 26 interferon-treated patients with chronic HBV who were coinfected with HIV. Based on results such as these, interferon therapy in the HBV/HIV-coinfected patient should be limited to patients who are likely to seroconvert: ie, those who are female and younger than 40 years with high ALT levels, low serum HBV DNA levels, and active liver histology (a subgroup that is more likely to undergo spontaneous seroconversion than other HBV-infected groups).
Standard or pegylated interferon is a treatment option for coinfected patients who do not yet require HAART, especially patients who have high ALT levels, low viral loads, and positive HBeAg status without liver decompensation. 
HBV AND HIV COINFECTION

Nucleoside and nucleotide analogues
The nucleoside and nucleotide analogues used for HBV therapy have different degrees of effectiveness against HIV polymerase, but none can be used as monotherapy because of the risk of inducing HIV resistance. Lamivudine and tenofovir are used as part of the standard cocktail for the treatment of HIV (see "Case: HIV/HBV with resistance to tenofovir," page S31). Entecavir is now recognized as a partial inhibitor of HIV replication. Both lamivudine and entecavir induce the YMDD mutation, an indication of resistance to therapy, in HIV polymerase. Tenofovir also may select for resistance mutations in HIV polymerase.
At dosages used for the treatment of HBV infection, adefovir has weak activity against HIV, and therefore HIV would not be under signifi cant selective pressure to develop resistance mutations. In HIV polymerase, the mutations that confer resistance to adefovir also confer resistance to tenofovir, and therefore use of adefovir may induce tenofovir resistance.
Telbivudine has not been studied in HIV-infected patients, but its resistance profi le is similar to that of lamivudine.
Treating both infections
When both HBV and HIV infections require treatment, HAART is necessary for HIV. 12 The treatment strategy for coinfection is to use standard therapy for HIV, selecting two agents that are effective against HBV infection.
The need to avoid antiviral resistance complicates the selection of active agents. Resistance to HIV therapy limits the choices for treatment of HBV infection. The immediate aim of therapy, an undetectable level of HBV DNA, eliminates the use of less potent agents. The best choice for therapy is the most potent agent that can be used, such as tenofovir plus lamivudine or tenofovir plus emtricitabine.
Antiviral resistance
For the coinfected patient who develops resistance to lamivudine, the recommendation is to treat with tenofovir plus entecavir (the preferable choice because of absence of cross-reactivity between the two agents) or tenofovir plus lamivudine or emtricitabine. There is some evidence that lamivudine resistance predisposes to entecavir resistance, but the studies that generated these results were conducted in patients who had very high baseline viral loads 13 ; the effectiveness of entecavir in patients with low baseline viral loads is unknown. Presumably, when entecavir is used in combination with another potent nucleoside analogue in coinfected patients, the sensitivity of HBV will be more durable than when entecavir is used as monotherapy.
Long-term monitoring
Long-term monitoring for the coinfected patient is similar to that for the patient infected with HBV only. HBV DNA levels should be monitored every 3 months for signs of resistance until levels have plateaued or become undetectable. Once the HBV DNA level is stable or undetectable, the monitoring interval can be extended. Ultrasonographic screening for hepatocellular carcinoma should be conducted every 6 months. Patients with cirrhosis should be screened for esophageal varices.
SUMMARY
HBV in the setting of HIV is more aggressive than in a patient infected with HBV only, and treatment must be comparably aggressive and carefully selected. The primary goal of HBV treatment in a coinfected patient is the same as in a patient with HBV infection only: reduction of viral load to undetectable levels. Treatment decisions are based on viral load, ALT level, fi ndings on liver biopsy, the need for HAART, and the drug's resistance profi le. None of the nucleoside or 2 A normal level (< 2,000 IU/mL) does not require immediate treatment; the decision to treat patients with a high HBV DNA level rests on measurement of alanine aminotransferase (ALT) and the degree of fi brosis on liver biopsy. The algorithm is not static, in that HBV is highly variable in its time to progression and requires constant monitoring. nucleotide analogues can be used as monotherapy in the coinfected patient because of the risk of inducing resistance to HIV therapy. When the patient requires HAART, then the general recommendation is to select a combination of two drugs that have activity against HIV. If resistance develops, the preferred strategy is treatment with tenofovir plus entecavir. Monitoring includes measurement of HBV DNA levels every 3 months and ultrasonographic screening for hepatocellular carcinoma every 6 months.
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